EffecTrial - 2025 - konkurs w ramach Partnerstwa ERA4Health (NCBR)

The aims of the call are:

• to support randomised, interventional and pragmatic comparative-effectiveness multi-country Investigator-Initiated Clinical Studies (IICS),
• to encourage and enable transnational collaboration between clinical/public health research teams (from hospital/ public health, healthcare settings and other healthcare organisations) that conduct comparative-effectiveness multi-country IICS.

Proposals should address all the 4 following points :

1. Be a pragmatic comparative effectiveness trial, designed as randomised interventional trial.
2. Compare the use of currently approved healthcare interventions either to each other or to the current standard of care. 
3. They shall consider healthcare interventions which could include but would not be limited to: diagnostic, screening, prevention and treatment interventions. The interventions can be pharmacological as well as non-pharmacological procedures like nutrition and/or lifestyle interventions, surgery, prognosis methods, use of medical devices, eHealth and digital interventions and other health interventions.
4. These interventions shall have high public relevance only in the fields of these specific diseases or conditions (that are of equal importance):

• • Cardiovascular diseases
  • Metabolic disorders
  • Nutrition and lifestyle-related diseases
  • Non-communicable respiratory diseases

The focus of the multi-country Investigator-Initiated Clinical Studies should primarily address at least one of the abovementioned principal diseases/conditions, although the proposals can also address several of the mentioned diseases/conditions and/or other related comorbidities. 

Beyond the research topics, the following requirements and recommendations should be considered (szczegóły w regulaminie konkursu – Call text). 

Out of scope: 

• Studies in other medical areas different from the ones mentioned above (cardiovascular diseases, metabolic disorders, nutrition and lifestyle-related diseases and non-communicable respiratory diseases).
• Particularly, those clinical trials that are focused on rare diseases, cancer and/or infectious diseases are out of the scope of this call, even if these diseases are studied with one of the eligible diseases/conditions 
• Proposals focused on observational studies, cohort studies, translational/clinical approval studies, creation of large databases, systematic reviews and meta-analysis.
• Basic biomedical research
• Development of a new healthcare intervention
• Phase I and phase II studies
• Placebo randomized controlled trials